TABLE 2.

Baseline demographic and clinical characteristics associated with fT3/fT4 ratio

Categorical variables
Variable	Level	n	fT3/fT4 ratio	p
Sex	Female	526	0.30 (0.27–0.34)	<0.001
	Male	469	0.32 (0.28–0.36)
Drug	Adalimumab	448	0.31 (0.28–0.35)	0.740
	Infliximab	547	0.31 (0.27–0.35)
Smoker	Current smoker	196	0.31 (0.27–0.34)	0.364
	Non‐current smoker	787	0.31 (0.27–0.35)
Corticosteroid use at baseline	Yes	293	0.28 (0.25–0.33)	<0.001
	No	702	0.32 (0.29–0.36)
Immunomodulator use at baseline	Yes	537	0.31 (0.27–0.36)	0.156
	No	458	0.31 (0.27–0.35)

Continuous variables
Variable	Spearman's Rho (R)	p
Age	−0.12	<0.001
Disease duration	0.06	0.046
BMI	0.12	<0.001
CRP a	−0.10	0.002
Faecal calprotectin a	−0.12	0.001

Abbreviation: CRP, C‐reactive protein.

^a Variables were log‐transformed for analysis.